SAB Biotherapeutics
SAB Biotherapeutics is a leading biopharmaceutical company dedicated to developing human antibody therapeutics using advanced polyclonal antibody science. They utilize a unique platform technology called DiversitAb™ to produce fully human antibodies in large animals, such as genetically engineered cattle, to fight various diseases including infectious diseases, autoimmune disorders, and cancers. Their mission is to change lives impacted by diseases like type 1 diabetes, Ebola, MERS, influenza, and more, through innovative, scalable, and rapid-response antibody therapies. The company is also pioneering the use of genetically engineered animals to produce human antibodies, which could provide scalable treatments for infectious diseases such as Ebola, Zika, and MERS, and is recognized by WHO as a promising platform technology.
Industries
Nr. of Employees
medium (51-250)
SAB Biotherapeutics
Sioux Falls, South Dakota, United States, North America
Products
Disease-modifying immunotherapy candidate for Type 1 Diabetes
A therapeutic immunotherapy intended to modify autoimmune processes in Type 1 Diabetes with the objective of preserving insulin-producing beta cell function and delaying disease progression.
Human polyclonal antibody therapeutics for emerging infectious diseases
Pipeline of human polyclonal antibody candidates generated from immunized production animals against multiple infectious disease targets, intended for therapeutic treatment or post-exposure prophylaxis.
Disease-modifying immunotherapy candidate for Type 1 Diabetes
A therapeutic immunotherapy intended to modify autoimmune processes in Type 1 Diabetes with the objective of preserving insulin-producing beta cell function and delaying disease progression.
Human polyclonal antibody therapeutics for emerging infectious diseases
Pipeline of human polyclonal antibody candidates generated from immunized production animals against multiple infectious disease targets, intended for therapeutic treatment or post-exposure prophylaxis.
Services
Production of clinical-grade human polyclonal antibodies from large animals
End-to-end service from antigen immunization of genetically engineered large animals through plasma collection, purification and release of clinical-grade IgG suitable for human trials.
Preclinical efficacy testing and in vivo model evaluation
Conduct of neutralization assays and efficacy studies in small-animal infection models to demonstrate protective activity of antibody preparations prior to clinical translation.
cGMP manufacturing and clinical product supply
Manufacture and supply of clinical-grade antibody material and related chemistry, manufacturing and controls (CMC) support to enable early-phase clinical trials.
Design and construction of specialized production facilities for animal-derived biologics
Site planning, construction integration and operational setup for greenfield facilities configured for housing production animals, plasma collection, veterinary operations and on-site biomanufacturing.
Production of clinical-grade human polyclonal antibodies from large animals
End-to-end service from antigen immunization of genetically engineered large animals through plasma collection, purification and release of clinical-grade IgG suitable for human trials.
Preclinical efficacy testing and in vivo model evaluation
Conduct of neutralization assays and efficacy studies in small-animal infection models to demonstrate protective activity of antibody preparations prior to clinical translation.
cGMP manufacturing and clinical product supply
Manufacture and supply of clinical-grade antibody material and related chemistry, manufacturing and controls (CMC) support to enable early-phase clinical trials.
Design and construction of specialized production facilities for animal-derived biologics
Site planning, construction integration and operational setup for greenfield facilities configured for housing production animals, plasma collection, veterinary operations and on-site biomanufacturing.
Expertise Areas
- Polyclonal antibody therapeutics
- Large-animal bioproduction for biologics
- Rapid-response therapeutic development for emerging pathogens
- Antigen design and immunization strategies
Key Technologies
- Genetically engineered large-animal antibody production
- Plasma collection and IgG purification
- Nucleic acid (DNA) and recombinant vaccine immunization
- Preclinical in vivo infection models (mouse, hamster)